What is the current valuation of the Asthma Disease Market as of 2024?

The Asthma Disease Market was valued at 26.22 USD Billion in 2024. Read More

What is the projected market valuation for the Asthma Disease Market in 2035?

The market is projected to reach 38.36 USD Billion by 2035. Read More

What is the expected CAGR for the Asthma Disease Market during the forecast period 2025 - 2035?

The expected CAGR for the Asthma Disease Market during 2025 - 2035 is 3.52%. Read More

Which treatment type segment had the highest valuation in 2024?

In 2024, the Controller Medications segment had the highest valuation at 12.0 USD Billion. Read More

What are the projected values for the Biologics segment by 2035?

The Biologics segment is projected to reach 10.0 USD Billion by 2035. Read More

How does the market valuation for Allergic Asthma compare to Non-Allergic Asthma in 2024?

In 2024, the market valuation for Allergic Asthma was 10.0 USD Billion, whereas Non-Allergic Asthma was valued at 8.0 USD Billion. Read More

Which age group is expected to have the highest market valuation in 2035?

By 2035, the Adults age group is expected to have the highest market valuation at 18.0 USD Billion. Read More

What is the projected market size for Severe Persistent asthma by 2035?

The market size for Severe Persistent asthma is projected to reach 14.86 USD Billion by 2035. Read More

Which key players are leading the Asthma Disease Market?

Key players in the Asthma Disease Market include GlaxoSmithKline, AstraZeneca, and Merck & Co. Read More

What is the expected growth trend for the Combination Therapy segment from 2024 to 2035?

The Combination Therapy segment is expected to grow from 7.22 USD Billion in 2024 to 9.36 USD Billion by 2035. Read More

Asthma Disease Market

Asthma Disease Market Research Report: Size, Share, Trend Analysis By Treatment Type (Controller Medications, Rescue Medications, Biologics, Combination Therapy), By Cause of Asthma (Allergic Asthma, Non-Allergic Asthma, Exercise-Induced Asthma, Occupational Asthma), By Severity (Mild Intermittent, Mild Persistent, Moderate Persistent, Severe Persistent), By Age Group (Children, Adolescents, Adults, Elderly) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

3.52%

2024 Market Size

$ 26.22 Billion

2035 Market Size

$ 38.36 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/32413-HCR | Pages: 128 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Treatment Type (USD Billion)
  1. 4.1.1 Controller Medications
  2. 4.1.2 Rescue Medications
  3. 4.1.3 Biologics
  4. 4.1.4 Combination Therapy
2. 4.2 Healthcare, BY Cause of Asthma (USD Billion)
  1. 4.2.1 Allergic Asthma
  2. 4.2.2 Non-Allergic Asthma
  3. 4.2.3 Exercise-Induced Asthma
  4. 4.2.4 Occupational Asthma
3. 4.3 Healthcare, BY Severity (USD Billion)
  1. 4.3.1 Mild Intermittent
  2. 4.3.2 Mild Persistent
  3. 4.3.3 Moderate Persistent
  4. 4.3.4 Severe Persistent
4. 4.4 Healthcare, BY Age Group (USD Billion)
  1. 4.4.1 Children
  2. 4.4.2 Adolescents
  3. 4.4.3 Adults
  4. 4.4.4 Elderly
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 GlaxoSmithKline (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 AstraZeneca (GB)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Boehringer Ingelheim (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Teva Pharmaceutical Industries (IL)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sanofi (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Merck & Co. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Pfizer (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Roche (CH)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 US MARKET ANALYSIS BY CAUSE OF ASTHMA
5. 6.5 US MARKET ANALYSIS BY SEVERITY
6. 6.6 US MARKET ANALYSIS BY AGE GROUP
7. 6.7 CANADA MARKET ANALYSIS BY TREATMENT TYPE
8. 6.8 CANADA MARKET ANALYSIS BY CAUSE OF ASTHMA
9. 6.9 CANADA MARKET ANALYSIS BY SEVERITY
10. 6.10 CANADA MARKET ANALYSIS BY AGE GROUP
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY CAUSE OF ASTHMA
14. 6.14 GERMANY MARKET ANALYSIS BY SEVERITY
15. 6.15 GERMANY MARKET ANALYSIS BY AGE GROUP
16. 6.16 UK MARKET ANALYSIS BY TREATMENT TYPE
17. 6.17 UK MARKET ANALYSIS BY CAUSE OF ASTHMA
18. 6.18 UK MARKET ANALYSIS BY SEVERITY
19. 6.19 UK MARKET ANALYSIS BY AGE GROUP
20. 6.20 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY CAUSE OF ASTHMA
22. 6.22 FRANCE MARKET ANALYSIS BY SEVERITY
23. 6.23 FRANCE MARKET ANALYSIS BY AGE GROUP
24. 6.24 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY CAUSE OF ASTHMA
26. 6.26 RUSSIA MARKET ANALYSIS BY SEVERITY
27. 6.27 RUSSIA MARKET ANALYSIS BY AGE GROUP
28. 6.28 ITALY MARKET ANALYSIS BY TREATMENT TYPE
29. 6.29 ITALY MARKET ANALYSIS BY CAUSE OF ASTHMA
30. 6.30 ITALY MARKET ANALYSIS BY SEVERITY
31. 6.31 ITALY MARKET ANALYSIS BY AGE GROUP
32. 6.32 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY CAUSE OF ASTHMA
34. 6.34 SPAIN MARKET ANALYSIS BY SEVERITY
35. 6.35 SPAIN MARKET ANALYSIS BY AGE GROUP
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY CAUSE OF ASTHMA
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY SEVERITY
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY AGE GROUP
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY TREATMENT TYPE
42. 6.42 CHINA MARKET ANALYSIS BY CAUSE OF ASTHMA
43. 6.43 CHINA MARKET ANALYSIS BY SEVERITY
44. 6.44 CHINA MARKET ANALYSIS BY AGE GROUP
45. 6.45 INDIA MARKET ANALYSIS BY TREATMENT TYPE
46. 6.46 INDIA MARKET ANALYSIS BY CAUSE OF ASTHMA
47. 6.47 INDIA MARKET ANALYSIS BY SEVERITY
48. 6.48 INDIA MARKET ANALYSIS BY AGE GROUP
49. 6.49 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY CAUSE OF ASTHMA
51. 6.51 JAPAN MARKET ANALYSIS BY SEVERITY
52. 6.52 JAPAN MARKET ANALYSIS BY AGE GROUP
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY CAUSE OF ASTHMA
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY SEVERITY
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY AGE GROUP
57. 6.57 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY CAUSE OF ASTHMA
59. 6.59 MALAYSIA MARKET ANALYSIS BY SEVERITY
60. 6.60 MALAYSIA MARKET ANALYSIS BY AGE GROUP
61. 6.61 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY CAUSE OF ASTHMA
63. 6.63 THAILAND MARKET ANALYSIS BY SEVERITY
64. 6.64 THAILAND MARKET ANALYSIS BY AGE GROUP
65. 6.65 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY CAUSE OF ASTHMA
67. 6.67 INDONESIA MARKET ANALYSIS BY SEVERITY
68. 6.68 INDONESIA MARKET ANALYSIS BY AGE GROUP
69. 6.69 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY CAUSE OF ASTHMA
71. 6.71 REST OF APAC MARKET ANALYSIS BY SEVERITY
72. 6.72 REST OF APAC MARKET ANALYSIS BY AGE GROUP
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY CAUSE OF ASTHMA
76. 6.76 BRAZIL MARKET ANALYSIS BY SEVERITY
77. 6.77 BRAZIL MARKET ANALYSIS BY AGE GROUP
78. 6.78 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY CAUSE OF ASTHMA
80. 6.80 MEXICO MARKET ANALYSIS BY SEVERITY
81. 6.81 MEXICO MARKET ANALYSIS BY AGE GROUP
82. 6.82 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY CAUSE OF ASTHMA
84. 6.84 ARGENTINA MARKET ANALYSIS BY SEVERITY
85. 6.85 ARGENTINA MARKET ANALYSIS BY AGE GROUP
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY CAUSE OF ASTHMA
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY SEVERITY
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY AGE GROUP
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY CAUSE OF ASTHMA
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY SEVERITY
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY AGE GROUP
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY CAUSE OF ASTHMA
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY SEVERITY
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY AGE GROUP
99. 6.99 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY CAUSE OF ASTHMA
101. 6.101 REST OF MEA MARKET ANALYSIS BY SEVERITY
102. 6.102 REST OF MEA MARKET ANALYSIS BY AGE GROUP
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY CAUSE OF ASTHMA, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY CAUSE OF ASTHMA, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY SEVERITY, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY SEVERITY, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.2.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.2.4 BY AGE GROUP, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.3.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.3.4 BY AGE GROUP, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.4.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.4.4 BY AGE GROUP, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.5.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.5.4 BY AGE GROUP, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.6.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.6.4 BY AGE GROUP, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.7.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.7.4 BY AGE GROUP, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.8.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.8.4 BY AGE GROUP, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.9.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.9.4 BY AGE GROUP, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.10.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.10.4 BY AGE GROUP, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.11.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.11.4 BY AGE GROUP, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.12.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.12.4 BY AGE GROUP, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.13.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.13.4 BY AGE GROUP, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.14.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.14.4 BY AGE GROUP, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.15.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.15.4 BY AGE GROUP, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.16.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.16.4 BY AGE GROUP, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.17.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.17.4 BY AGE GROUP, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.18.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.18.4 BY AGE GROUP, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.19.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.19.4 BY AGE GROUP, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.20.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.20.4 BY AGE GROUP, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.21.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.21.4 BY AGE GROUP, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.22.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.22.4 BY AGE GROUP, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.23.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.23.4 BY AGE GROUP, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.24.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.24.4 BY AGE GROUP, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.25.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.25.4 BY AGE GROUP, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.26.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.26.4 BY AGE GROUP, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.27.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.27.4 BY AGE GROUP, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.28.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.28.4 BY AGE GROUP, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.29.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.29.4 BY AGE GROUP, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY CAUSE OF ASTHMA, 2025-2035 (USD Billion)
  3. 7.30.3 BY SEVERITY, 2025-2035 (USD Billion)
  4. 7.30.4 BY AGE GROUP, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Asthma Disease Market Segmentation

Asthma Disease Market By Treatment Type (USD Billion, 2025-2035)

Controller Medications
Rescue Medications
Biologics
Combination Therapy

Asthma Disease Market By Cause of Asthma (USD Billion, 2025-2035)

Allergic Asthma
Non-Allergic Asthma
Exercise-Induced Asthma
Occupational Asthma

Asthma Disease Market By Severity (USD Billion, 2025-2035)

Mild Intermittent
Mild Persistent
Moderate Persistent
Severe Persistent

Asthma Disease Market By Age Group (USD Billion, 2025-2035)

Children
Adolescents
Adults
Elderly

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”